{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T15:19:16Z","timestamp":1772119156943,"version":"3.50.1"},"reference-count":13,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,5,24]],"date-time":"2025-05-24T00:00:00Z","timestamp":1748044800000},"content-version":"vor","delay-in-days":23,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005743","name":"Universit\u00e0 Cattolica del Sacro Cuore","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005743","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2025,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>A real-life study on CPX-351 and the standard arm (\u20187\u2009+\u20093\u2019) of the CPX-351 registrative trial in adults with secondary Acute Myeloid Leukemia were compared by an unanchored Matching-adjusted indirect comparison (MAIC), in order to evaluate the efficacy and toxicity of CPX-351. Results of this study are important to confirm the role of CPX-351 in significantly improving survival and remission rates compared with \u20187\u2009+\u20093\u2019 with a good safety profile in AML patients with high-risk features, a target group traditionally with a very poor prognosis. Moreover, this pilot analysis underlines the potentiality of the statistical method to compare studies with strong differences.<\/jats:p>","DOI":"10.1007\/s00277-025-06381-3","type":"journal-article","created":{"date-parts":[[2025,5,23]],"date-time":"2025-05-23T23:10:03Z","timestamp":1748041803000},"page":"2731-2736","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Matching-adjusted indirect comparison of CPX- 351 in secondary Acute Myeloid Leukemia between the registrative trial and a real-life study"],"prefix":"10.1007","volume":"104","author":[{"given":"Luana","family":"Fianchi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alfonso","family":"Piciocchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabio","family":"Guolo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Marchesi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giovanni","family":"Marsili","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chiara","family":"Cattaneo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michele","family":"Gottardi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Restuccia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Candoni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elettra","family":"Ortu La Barbera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rita","family":"Fazzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Crescenza","family":"Pasciolla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olimpia","family":"Finizio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicola","family":"Fracchiolla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mario","family":"Delia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Federica","family":"Lessi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michela","family":"Dargenio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valentina","family":"Bonuomo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Ilaria","family":"Del Principe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrizia","family":"Zappasodi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco","family":"Picardi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudia","family":"Basilico","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Monica","family":"Piedimonte","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paola","family":"Minetto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrizia","family":"Chiusolo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lucia","family":"Prezioso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caterina","family":"Buquicchio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lorella","family":"Melillo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniele","family":"Zama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesca","family":"Farina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valentina","family":"Mancini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michela","family":"Rondoni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandro","family":"Busca","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Livio","family":"Pagano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,5,24]]},"reference":[{"key":"6381_CR1","doi-asserted-by":"crossref","unstructured":"Guolo F, Fianchi L, Minetto P, Clavio M, Gottardi M, Galimberti S, et al. CPX-351 treatment in secondary acute myeloblastic leukemia is effective and improves the feasibility of allogeneic stem cell transplantation: results of the Italian compassionate use program. Blood Cancer J [Internet]. 2020 Oct 1 [cited 2024 Mar 31];10(10). Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/33024084\/","DOI":"10.1038\/s41408-020-00361-8"},{"key":"6381_CR2","doi-asserted-by":"crossref","unstructured":"Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood [Internet]. 2016 May 19 [cited 2024 Mar 31];127(20):2391\u2013405. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/27069254\/","DOI":"10.1182\/blood-2016-03-643544"},{"key":"6381_CR3","doi-asserted-by":"crossref","unstructured":"\u00d8stg\u00e5rd LSG, Medeiros BC, Sengel\u00f8v H, N\u00f8rgaard M, Andersen MK, Dufva I, et al. Epidemiology and Clinical Significance of Secondary and Therapy-Related Acute Myeloid Leukemia: A National Population-Based Cohort Study. J Clin Oncol [Internet]. 2015 Nov 1 [cited 2024 Mar 31];33(31):3641\u20139. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/26304885\/","DOI":"10.1200\/JCO.2014.60.0890"},{"key":"6381_CR4","doi-asserted-by":"crossref","unstructured":"Nagel G, Weber D, Fromm E, Erhardt S, L\u00fcbbert M, Fiedler W, et al. Epidemiological, genetic, and clinical characterization by age of newly diagnosed acute myeloid leukemia based on an academic population-based registry study (AMLSG BiO). Ann Hematol [Internet]. 2017 Dec 1 [cited 2024 Mar 31];96(12):1993\u20132003. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/29090343\/","DOI":"10.1007\/s00277-017-3150-3"},{"key":"6381_CR5","doi-asserted-by":"crossref","unstructured":"Lancet JE, Uy GL, Cortes JE, Newell LF, Lin TL, Ritchie EK, et al. CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid Leukemia. J Clin Oncol [Internet]. 2018 Sep 10 [cited 2024 Mar 31];36(26):2684\u201392. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/30024784\/","DOI":"10.1200\/JCO.2017.77.6112"},{"key":"6381_CR6","doi-asserted-by":"crossref","unstructured":"Lancet JE, Uy GL, Newell LF, Lin TL, Ritchie EK, Stuart RK, et al. CPX-351 versus 7+3 cytarabine and daunorubicin chemotherapy in older adults with newly diagnosed high-risk or secondary acute myeloid leukaemia: 5-year results of a randomised, open-label, multicentre, phase 3 trial. Lancet Haematol [Internet]. 2021 Jul 1 [cited 2024 Mar 31];8(7):e481\u201391. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/34171279\/","DOI":"10.1016\/S2352-3026(21)00134-4"},{"key":"6381_CR7","doi-asserted-by":"crossref","unstructured":"Fianchi L, Guolo F, Marchesi F, Cattaneo C, Gottardi M, Restuccia F, et al. Multicenter Observational Retrospective Study on Febrile Events in Patients with Acute Myeloid Leukemia Treated with Cpx-351 in \u201cReal-Life\u201d: The SEIFEM Experience. Cancers (Basel) [Internet]. 2023 Jul 1 [cited 2024 Mar 31];15(13). Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/37444567\/","DOI":"10.3390\/cancers15133457"},{"key":"6381_CR8","doi-asserted-by":"crossref","unstructured":"Signorovitch JE, Sikirica V, Erder MH, Xie J, Lu M, Hodgkins PS, et al. Matching-adjusted indirect comparisons: a new tool for timely comparative effectiveness research. Value Health [Internet]. 2012 Sep [cited 2024 Mar 31];15(6):940\u20137. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/22999145\/","DOI":"10.1016\/j.jval.2012.05.004"},{"key":"6381_CR9","doi-asserted-by":"crossref","unstructured":"Cortes JE, Goldberg SL, Feldman EJ, Rizzeri DA, Hogge DE, Larson M, et al. Phase II, multicenter, randomized trial of CPX-351 (cytarabine:daunorubicin) liposome injection versus intensive salvage therapy in adults with first relapse AML. Cancer [Internet]. 2015 Jan 15 [cited 2024 Mar 31];121(2):234\u201342. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/25223583\/","DOI":"10.1002\/cncr.28974"},{"key":"6381_CR10","doi-asserted-by":"crossref","unstructured":"Lancet JE, Cortes JE, Hogge DE, Tallman MS, Kovacsovics TJ, Damon LE, et al. Phase 2 trial of CPX-351, a fixed 5:1 molar ratio of cytarabine\/daunorubicin, vs cytarabine\/daunorubicin in older adults with untreated AML. Blood [Internet]. 2014 May 22 [cited 2024 Mar 31];123(21):3239\u201346. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/24687088\/","DOI":"10.1182\/blood-2013-12-540971"},{"key":"6381_CR11","doi-asserted-by":"crossref","unstructured":"Issa GC, Kantarjian HM, Xiao L, Ning J, Alvarado Y, Borthakur G, et al. Phase II trial of CPX-351 in patients with acute myeloid leukemia at high risk for induction mortality. Leukemia 2020 34:11 [Internet]. 2020 Jun 16 [cited 2024 Sep 5];34(11):2914\u201324. Available from: https:\/\/www.nature.com\/articles\/s41375-020-0916-8","DOI":"10.1038\/s41375-020-0916-8"},{"key":"6381_CR12","doi-asserted-by":"publisher","unstructured":"Chiche E, Rahme R, Bertoli S, Dumas PY, Micol JB, Hicheri Y, et al. Real-life experience with CPX-351 and impact on the outcome of high-risk AML patients: a multicentric French cohort. Blood Adv [Internet]. 2021 Jan 12 [cited 2024 Sep 5];5(1):176\u201384. Available from: https:\/\/doi.org\/10.1182\/bloodadvances.2020003159","DOI":"10.1182\/bloodadvances.2020003159"},{"key":"6381_CR13","doi-asserted-by":"crossref","unstructured":"Roboz GJ, Larson ML, Rubenstein SE, Solomon SR, Schiller GJ, An Q, et al. Final safety and efficacy results from the CPX-351 early access program for older patients with high-risk or secondary acute myeloid leukemia. Leuk Lymphoma [Internet]. 2020 Apr 15 [cited 2024 Sep 5];61(5):1188\u201394. Available from: https:\/\/www.tandfonline.com\/doi\/abs\/10.1080\/10428194.2020.1725503","DOI":"10.1080\/10428194.2020.1725503"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-025-06381-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-025-06381-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-025-06381-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,5]],"date-time":"2025-06-05T02:37:46Z","timestamp":1749091066000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-025-06381-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":13,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["6381"],"URL":"https:\/\/doi.org\/10.1007\/s00277-025-06381-3","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-5915486\/v1","asserted-by":"object"}]},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"28 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}